Published in Clin Breast Cancer on April 01, 2010
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2015) 1.85
Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol (2011) 0.94
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs (2012) 0.93
Eribulin mesylate in the treatment of metastatic breast cancer. Biologics (2012) 0.92
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment. Mar Drugs (2011) 0.91
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. Onco Targets Ther (2011) 0.89
Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer (2013) 0.88
Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat (2011) 0.87
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract (2012) 0.85
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol (2013) 0.83
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health (2015) 0.82
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer. Breast Cancer (Dove Med Press) (2011) 0.81
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res (2014) 0.80
Carcinomatous pericarditis in 3 breast cancer patients with long-term survival. Case Rep Oncol (2012) 0.75
Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings. Breast Cancer (Auckl) (2015) 0.75
Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea. Clinicoecon Outcomes Res (2016) 0.75
Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemother Pharmacol (2017) 0.75
Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7). Pharmacogn Mag (2017) 0.75
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2007) 4.23
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol (2010) 3.32
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol (2010) 2.52
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology (2009) 2.45
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 2.36
Image-guided optical spectroscopy provides molecular-specific information in vivo: MRI-guided spectroscopy of breast cancer hemoglobin, water, and scatterer size. Opt Lett (2007) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res (2012) 2.00
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res (2011) 1.78
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol (2013) 1.77
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res (2012) 1.57
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer (2007) 1.42
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat (2014) 1.32
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer (2004) 1.29
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn (2003) 1.28
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
In vivo quantitative imaging of normal and cancerous breast tissue using broadband diffuse optical tomography. Med Phys (2010) 1.23
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol (2004) 1.16
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell (2013) 1.14
Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? Radiology (2011) 1.14
Fast 3-d tomographic microwave imaging for breast cancer detection. IEEE Trans Med Imaging (2012) 1.13
Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat (2007) 1.11
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2014) 1.10
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer (2005) 1.09
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat (2010) 1.05
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Re: time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. J Natl Cancer Inst (2013) 1.05
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience. Breast Cancer Res (2013) 1.05
Molecular pathways: targeting hsp90--who benefits and who does not. Clin Cancer Res (2012) 1.04
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer (2011) 1.04
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment. Int J Hyperthermia (2013) 1.00
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res (2003) 0.96
Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol (2012) 0.95
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Ther (2004) 0.95
Eribulin mesylate. Clin Cancer Res (2011) 0.93
Psychological impact, support and information needs for women with an abnormal Pap smear: comparative results of a questionnaire in three European countries. BMC Womens Health (2011) 0.93
Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. Clin Breast Cancer (2012) 0.93
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori (2011) 0.91
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab (2012) 0.90
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res (2015) 0.90
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist (2014) 0.89
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res (2005) 0.89
Developments in quantitative oxygen-saturation imaging of breast tissue in vivo using multispectral near-infrared tomography. Antioxid Redox Signal (2007) 0.88
Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist (2012) 0.88
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist (2013) 0.88
Changes in breast cancer reports after pathology second opinion. Breast J (2014) 0.87
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Res Treat (2011) 0.86
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology (2014) 0.84
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res (2005) 0.84
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer (2014) 0.84
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol (2013) 0.83
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infect Dis (2012) 0.83
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res (2013) 0.82
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat (2010) 0.82
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Invest New Drugs (2008) 0.82
The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers. Altern Ther Health Med (2010) 0.82
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. J Clin Oncol (2009) 0.82
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res (2013) 0.82
Epothilones: clinical update and future directions. Oncology (Williston Park) (2008) 0.82
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs (2012) 0.81
Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast (2012) 0.81
Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective. Breast Cancer Res Treat (2008) 0.81
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther (2012) 0.80
Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif (2005) 0.80
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol (2008) 0.80
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs (2010) 0.80
Pilot study assessment of dynamic vascular changes in breast cancer with near-infrared tomography from prospectively targeted manipulations of inspired end-tidal partial pressure of oxygen and carbon dioxide. J Biomed Opt (2013) 0.79
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat (2013) 0.79